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S6 Journal of Thoracic Oncology Vol. 11 No. 2SIn CT-based lung cancer screening and incidentally
detected indeterminate pulmonary nodules, radiomics
has shown value in improving diagnostic accuracy to
discriminate cancer from benign pulmonary nodules. We
have analyzed data from the National Lung Screening
Trial, NLST, to identify subjects with cancerous and
benign nodules, and have organized them into cohorts
based on their screening history. Patients who are
diagnosed with cancer following a prior nodule-negative
screen have signiﬁcantly worse outcome than patients
who develop cancer following a prior nodule-positive/
cancer-negative screen. In cohorts of patients with
nodules not diagnosed as cancer in the ﬁrst screen, we
have identiﬁed signiﬁcant radiomic features that can
discriminate those who will subsequently develop can-
cer from those that remain benign with an accuracy of
80%, and this can be the basis for a “radiomics risk
score” to predict subsequent cancer development.
However, even the seemingly large “big data” NLST data
set is underpowered once cohorts are assembled with
similar histories, and co-variates are accounted for. So-
lutions to the problem of generating sufﬁciently powered
data sets include capturing the radiomic data at the point
of care (i.e. by the radiologists) and inter-institutional
sharing of images, data, features and algorithms, which
have yet to be reliably implemented.From bench to bedside to beam:
Hippocampal-sparing during cranial
irradiationVinai Gondi Northwestern Medicine Cancer
Center, Warrenville, ILWhole-brain radiotherapy either therapeutically for
brain metastases or prophylactically for small-cell lung
cancer has been associated with cognitive toxicity, in the
form of decline primarily in list-learning recall as well as
patient-reported cognitive functioning. Emerging evi-
dence suggests that the pathogenesis of radiotherapy-
induced cognitive deﬁcits may involve radiation-
induced injury to proliferating neural stem cells in the
subgranular zone of the hippocampus. Conformal
avoidance of this hippocampal neural stem cell
compartment during whole-brain radiotherapy using
intensity-modulated radiotherapy has been proposed as
an approach to preserving hippocampal neurogenesis
and thus preventing or mitigating radiotherapy-related
cognitive toxicity.
Promising results as compared to historical controls
were observed in RTOG 0933, a phase II study of hip-
pocampal avoidant WBRT for patients with brain me-
tastases. Validation of these results in a phase III settingis being pursued through NRG CC001, a phase III trial of
memantine plus whole-brain radiotherapy with or
without hippocampal avoidance for brain metastases.
Extrapolation of these results to the setting of prophy-
lactic cranial irradiation for small cell lung cancer is
being explored through NRG CC003, a randomized phase
II/III trial of prophylactic cranial irradiation with or
without hippocampal avoidance for small cell lung can-
cer. Both trials are currently activated and accruing
patients.
This presentation will review the biology and radio-
sensitivity of the hippocampal neural stem cell compart-
ment and prior and ongoing clinical studies to
corroborate these preclinical observations using
advanced radiotherapy techniques.Primary and adaptive resistance to
checkpoint blockade in lung cancerPeter Hammerman Dana-Farber Cancer
Institute, Boston, MAThe incorporation of immunotherapies, and most
notably immune checkpoint inhibitors, into the man-
agement of non-small cell lung cancer (NSCLC) has led to
a paradigm shift in the management of patients with
advanced disease. While PD1 antagonists have been
shown to be superior to standard chemotherapy for
subjects with progressive advanced disease many other
immunomodulatory agents are currently under investi-
gation as single agents or in combination with other
therapies.
While the lung cancer community has made great
strides in identifying genomic alterations in cancers
which are associated with speciﬁc therapeutic vulnera-
bilities, our knowledge regarding predictive biomarkers
for immunotherapies is limited. It remains the case that
only a minority of patients respond to PD1:PDL1 an-
tagonists, and for those who do, resistance to therapy
develops over time.
Here, I will present data describing our efforts in
proﬁling mouse models and patient specimens to
describe two modes of resistance to PD1:PDL1 ther-
apy. The ﬁrst centers on primary non-response in
patients with KRAS mutated lung cancers, tumors
which typically display high rates of somatic muta-
tions. I will present data demonstrating that within
KRAS mutated lung adenocarcinoma tumors with
concurrent loss of STK11/LKB1 display an adverse
immune microenvironment for PD1:PDL1 therapy. I
will discuss speciﬁc features of this immune micro-
environment and suggest strategies to overcome pri-
mary resistance.
